Core Viewpoint - The company announced that its wholly-owned subsidiary, Xi'an Jingxi Shuanghe Pharmaceutical Co., Ltd., has received a drug registration certificate for the balanced salt irrigation solution from the National Medical Products Administration, which is expected to enhance the company's product line and market competitiveness [1][4]. Group 1: Drug Registration Certificate - The balanced salt irrigation solution is a sterile electrolyte solution suitable for surgical irrigation [1]. - The research and development of this drug began in January 2022, with the application for market approval submitted in April 2024 and the approval granted in February 2026 [1][2]. Group 2: Market Situation - The balanced salt irrigation solution was developed by ICU MEDICAL INC and was approved for sale in the U.S. in February 1978 under the brand name "Physiosol." It has not been marketed in China [3]. - In 2024, the global sales of balanced salt irrigation solutions are projected to be approximately $3.34 million [3]. - In the Chinese market, there are 10 approved manufacturers of balanced salt irrigation solutions, with only 3 having passed or been deemed to have passed the consistency evaluation, including Jingxi Shuanghe [3]. Group 3: Financial Investment - The total R&D investment for the balanced salt irrigation solution has reached approximately RMB 3.65 million (unaudited) [2].

Core Viewpoint - Chengdu Yuandong Pharmaceutical Co., Ltd. has participated in the continuation procurement of drugs whose agreements have expired under the national organization procurement program, with 13 products proposed for selection in this round [1][2]. Group 1: Proposed Selected Products - The proposed selected products include 12 that were previously selected in the first to eighth batches of the national organization procurement, and one new product, Paricalcitol Injection [2]. - The total expected sales revenue from these products is approximately 651.20 million yuan for 2024, accounting for 48.25% of the company's total revenue for that year [2]. - For the first nine months of 2025, the expected sales revenue is about 504.08 million yuan, representing 49.46% of the company's total revenue for that period [2]. Group 2: Impact on the Company - The procurement cycle for these selected products will run from the actual execution date of the selection results until December 31, 2028, with medical institutions prioritizing the use of these selected drugs [2]. - The overall procurement is expected to maintain price stability or further decline, providing medical institutions with greater choice and ensuring continuity in clinical medication [2]. - Although some selected products may see a decrease in price compared to previous sales, having 13 products proposed for selection allows the company to solidify its market share and enhance the accessibility of these drugs [2].

Core Viewpoint - The company, Yuandong Biotech (688513.SH), has participated in the procurement process for the continuation of drugs whose agreements from the national centralized procurement have expired, with 13 products proposed for selection in this round [1][2]. Group 1: Procurement Details - The company has submitted applications for the continuation procurement organized by Jiangsu, Henan, and Guangdong provinces [1]. - The proposed selected products include 12 that were previously selected in the first to eighth batches of national centralized procurement and one new product, Paricalcitol Injection [1]. - The sales revenue from these products is projected to be approximately 651.20 million yuan in 2024, accounting for 48.25% of the company's total revenue for that year [1]. Group 2: Impact on Revenue - For the period from January to September 2025, the expected sales revenue from these products is about 504.08 million yuan, representing 49.46% of the company's total revenue for that period [1]. - The procurement cycle will last until December 31, 2028, during which medical institutions will prioritize the selected drugs, ensuring the completion of agreed procurement volumes [2]. Group 3: Market Stability - The overall pricing of the procurement is expected to remain stable or decrease further, providing medical institutions with greater choice and ensuring continuity in clinical medication [2]. - Although some selected products may see a price decrease compared to original sales prices, the selection of 13 products allows the company to maintain its market share and enhance the accessibility of these drugs [2].